Comparative Pharmacology
Head-to-head clinical analysis: HUMIRA versus RENFLEXIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMIRA versus RENFLEXIS.
HUMIRA vs RENFLEXIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tumor necrosis factor alpha (TNF-α) inhibitor; a recombinant human IgG1 monoclonal antibody that binds to soluble and membrane-bound TNF-α, preventing its interaction with p55 and p75 TNF receptors, thereby reducing inflammation and immune activation.
Renflexis (infliximab-abda) is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory activity. It inhibits TNFα binding to its receptors (TNFR1 and TNFR2), reducing inflammatory cell migration, cytokine production, and tissue damage.
Adult: 40 mg subcutaneously every other week. For ulcerative colitis: initial dose 160 mg on day 1, then 80 mg on day 15, then 40 mg every other week starting day 29.
5 mg/kg intravenously over at least 2 hours at 0, 2, and 6 weeks, then every 8 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 10–20 days) in adults, supporting a subcutaneous dosing interval of every 2 weeks. Longer half-life in older patients.
Terminal elimination half-life approximately 18-21 days (mean ~20 days) in patients with rheumatoid arthritis; supports every-8-week dosing interval.
Adalimumab is primarily eliminated via reticuloendothelial system degradation; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Primarily eliminated via reticuloendothelial system degradation; renal excretion accounts for <1% of dose as unchanged drug; no significant biliary or fecal excretion.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor